Razoxane, (R)- | CAS#24613-06-7 | antiangiogenic agent

MedKoo Cat#: 598748 | Name: Razoxane, (R)-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Razoxane, (R)- exhibits antiangiogenic effects.

Chemical Structure

Razoxane, (R)-

CAS#24613-06-7

Theoretical Analysis

MedKoo Cat#: 598748

Name: Razoxane, (R)-

CAS#: 24613-06-7

Chemical Formula: C11H16N4O4

Exact Mass: 268.1172

Molecular Weight: 268.27

Elemental Analysis: C, 49.25; H, 6.01; N, 20.88; O, 23.85

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Razoxane, (R)-; ICRF-186; ICRF 186; ICRF186; NSC-169779; NSC 169779; NSC169779; Levrazoxane;

IUPAC/Chemical Name

(R)-4,4'-(propane-1,2-diyl)bis(piperazine-2,6-dione)

InChi Key

BMKDZUISNHGIBY-SSDOTTSWSA-N

InChi Code

InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m1/s1

SMILES Code

C[C@@H](N(C1)CC(NC1=O)=O)CN(C2)CC(NC2=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 268.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Limat S, Daguindau E, Cahn JY, Nerich V, Brion A, Perrin S, Woronoff-Lemsi MC, Deconinck E. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma. J Clin Pharm Ther. 2014 Apr;39(2):168-74. doi: 10.1111/jcpt.12124. Epub 2014 Jan 3. PubMed PMID: 24384030. 2: Chow EJ, Asselin BL, Schwartz CL, Doody DR, Leisenring WM, Aggarwal S, Baker KS, Bhatia S, Constine LS, Freyer DR, Lipshultz SE, Armenian SH. Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. J Clin Oncol. 2015 Aug 20;33(24):2639-45. doi: 10.1200/JCO.2014.59.4473. Epub 2015 May 26. PubMed PMID: 26014292; PubMed Central PMCID: PMC4534526. 3: Anderson H, Yap JT, Wells P, Miller MP, Propper D, Price P, Harris AL. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer. 2003 Jul 21;89(2):262-7. PubMed PMID: 12865914; PubMed Central PMCID: PMC2394254. 4: Klenner T, Wingen F, Keppler B, Valenzuela-Paz P, Amelung F, Schmähl D. Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat. Clin Exp Metastasis. 1990 Jul-Aug;8(4):345-59. PubMed PMID: 2350920. 5: Sun F, Qi X, Geng C, Li X. Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity. Am J Med Sci. 2015 May;349(5):406-12. doi: 10.1097/MAJ.0000000000000432. PubMed PMID: 25723884. 6: Neckář J, Boudíková A, Mandíková P, Stěrba M, Popelová O, Mikšík I, Dabrowská L, Mráz J, Geršl V, Kolář F. Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts. Can J Physiol Pharmacol. 2012 Sep;90(9):1303-10. doi: 10.1139/y2012-096. Epub 2012 Aug 22. PubMed PMID: 22913659. 7: Kamat P, Vandenberghe S, Christen S, Bongoni AK, Meier B, Rieben R, Khattab AA. Dexrazoxane Shows No Protective Effect in the Acute Phase of Reperfusion during Myocardial Infarction in Pigs. PLoS One. 2016 Dec 21;11(12):e0168541. doi: 10.1371/journal.pone.0168541. eCollection 2016. PubMed PMID: 28002439; PubMed Central PMCID: PMC5176296. 8: Hasinoff BB. Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab Dispos. 1993 Sep-Oct;21(5):883-8. PubMed PMID: 7902252. 9: Baldwin JR, Lewis RC, Phillips BA, Overmyer SK, Hatfield NZ, Narang PK. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. Biopharm Drug Dispos. 1996 Aug;17(6):541-50. PubMed PMID: 8866044. 10: Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K, Andoh T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res. 1991 Sep 15;51(18):4909-16. PubMed PMID: 1654205. 11: Vigevani A, Zampieri M, Pellizzato R. Thermal behaviour and binary phase diagram of (S)-(+)-4,4'-(1-methyl-1,2-ethandiyl)-bis-(2,6-piperazinedione) (dexrazoxane), a cardioprotective agent, and of its (R)-(-)-enantiomer. J Pharm Biomed Anal. 1992 Jan;10(1):31-6. PubMed PMID: 1391080. 12: Sargent JM, Williamson CJ, Yardley C, Taylor CG, Hellmann K. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562. Br J Cancer. 2001 Apr 6;84(7):959-64. PubMed PMID: 11286477; PubMed Central PMCID: PMC2363849. 13: Rhomberg W, Gruber-Mösenbacher U, Eiter H, Fritzsche H, Breitfellner G. [Prognosis and epidemiology of malignant hemangioendotheliomas of the thyroid gland]. Schweiz Med Wochenschr. 1993 Sep 4;123(35):1640-4. German. PubMed PMID: 8211014. 14: Thirupathi C, Nagesh Kumar K, Srinivasu G, Lakshmi Narayana C, Parameswara Murthy C. Development and Validation of Stereo Selective Method for the Separation of Razoxane Enantiomers in Hydrophilic Interaction Chromatography. J Chromatogr Sci. 2018 Feb 1;56(2):147-153. doi: 10.1093/chromsci/bmx094. PubMed PMID: 29140426. 15: Xue Y, Guo Y, Xie X. Translocation t(7;11)(P15;P15) in a patient with therapy-related acute myeloid leukemia following bimolane and ICRF-154 treatment for psoriasis. Leuk Res. 1997 Feb;21(2):107-9. PubMed PMID: 9112426. 16: Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol. 1995 Sep 28;50(7):953-8. PubMed PMID: 7575679. 17: Xue Y, Lu D, Guo Y, Lin B. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leuk Res. 1992 Nov;16(11):1113-23. PubMed PMID: 1434747. 18: Potácová A, Adamcová M, Cajnáková H, Hrbatová L, Sterba M, Popelová O, Simůnek T, Ponka P, Gersl V. Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy: a useful tool for assessment of cardioprotective agents. Physiol Res. 2007;56(2):251-4. PubMed PMID: 17504005. 19: Loyevsky M, Sacci JB Jr, Boehme P, Weglicki W, John C, Gordeuk VR. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol. 1999 Feb;91(2):105-14. PubMed PMID: 9990337. 20: Diop NK, Vitellaro LK, Arnold P, Shang M, Marusak RA. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. J Inorg Biochem. 2000 Feb;78(3):209-16. PubMed PMID: 10805177.